BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Phase 2

Completed

Conditions: Gastric Cancer
Cancer of the Stomach
Esophagogastric Junction

Interventions: Biological: BMS-986213
Biological: Nivolumab
Drug: XELOX
Drug: FOLFOX
Drug: SOX

First Posted Date: 2018-09-07

Last Posted Date: 2024-02-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 274

Registration Number: NCT03662659

Locations: 🇩🇪
Local Institution - 0014, Frankfurt, Germany
🇺🇸
Local Institution - 0040, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

and more 76 locations

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Urinary Bladder Neoplasms
Muscle-Invasive Bladder Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-09-07

Last Posted Date: 2024-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 861

Registration Number: NCT03661320

Locations: 🇫🇮
Local Institution - 0146, Turku, Finland
🇩🇪
Local Institution - 0013, Herne, Germany
🇧🇪
Local Institution - 0060, Bruxelles, Belgium

and more 168 locations

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986310
Biological: Nivolumab

First Posted Date: 2018-09-07

Last Posted Date: 2021-11-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT03661632

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 2 locations

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: MMF

First Posted Date: 2018-09-06

Last Posted Date: 2018-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT03660436

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Withdrawn

Conditions: Multiple Myeloma

Interventions: Other: Non-Interventional

First Posted Date: 2018-09-06

Last Posted Date: 2022-05-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03660072

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Phase 1

Completed

Conditions: Neoplasms by Site

Interventions: Biological: nivolumab
Drug: rHuPH20

First Posted Date: 2018-09-04

Last Posted Date: 2024-12-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 139

Registration Number: NCT03656718

Locations: 🇺🇸
Local Institution - 0012, Eugene, Oregon, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Local Institution - 0011, Tyler, Texas, United States

and more 33 locations

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

Completed

Conditions: Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2018-08-23

Last Posted Date: 2024-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1056

Registration Number: NCT03644498

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Other: Placebo

First Posted Date: 2018-08-17

Last Posted Date: 2020-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT03634995

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Phase 1

Completed

Conditions: Cardiac Failure
Myocardial Failure

Interventions: Drug: BMS-986224

First Posted Date: 2018-08-17

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT03634969

Locations: 🇺🇸
Prism Research, Saint Paul, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: NKTR-214
Biological: Nivolumab

First Posted Date: 2018-08-17

Last Posted Date: 2024-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 783

Registration Number: NCT03635983

Locations: 🇦🇺
Local Institution - 0146, Coffs Harbour, New South Wales, Australia
🇺🇸
Local Institution - 0037, Cleveland, Ohio, United States
🇺🇸
Local Institution - 0135, Saint Louis, Missouri, United States

and more 161 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy